伐尼克兰用于青少年尼古丁电子烟戒断:一项随机临床试验
这项三组随机临床试验在16至25岁每日或近乎每日吸电子烟且不规律吸烟的青少年中,比较12周双盲伐尼克兰与安慰剂(均加简短远程行为咨询)及单盲增强常规照护。伐尼克兰组第9至12周持续戒断率51% vs 安慰剂14%(aOR 6.5,95%CI 3.0-14.1,P<.001),第9至24周28% vs 7%(aOR 6.0,95%CI 2.1-16.9,P<.001)。
要点
- 伐尼克兰加行为咨询提高青少年电子烟戒断率,第9至12周51% vs 安慰剂14%。
- 第9至24周持续戒断率伐尼克兰28% vs 安慰剂7%,aOR 6.0(95%CI 2.1-16.9)。
- 伐尼克兰组与增强常规照护比较亦显示更高戒断率,安慰剂与增强常规照护无显著差异。
核心结论
- 伐尼克兰联合行为咨询可提高吸尼古丁电子烟且不规律吸烟青少年的电子烟戒断率。
研究设计与样本
- 三组随机临床试验,比较12周双盲伐尼克兰与安慰剂(均加简短远程行为咨询)及单盲增强常规照护,每月随访至24周。
- 研究对象为16至25岁每日或近乎每日吸尼古丁电子烟、不规律吸烟且希望减少或戒断电子烟的青少年,于2022年6月至2024年5月在美国单一州开展,数据收集于2024年5月28日结束。
- 共随机261名参与者(平均年龄21.4岁,53%为女性),254名完成试验(97.3%)。
- 随机分组为1:1:1:伐尼克兰组(n=88,7天内滴定至1 mg每日两次的标准滴定方案,每周咨询并转介至短信戒断支持This is Quitting [TIQ])、安慰剂组(n=87,相同安慰剂、每周咨询并转介至TIQ)、增强常规照护组(n=86,仅转介至TIQ)。
主要发现
- 伐尼克兰组与安慰剂组第9至12周持续戒断率分别为51% vs 14%(aOR 6.5,95%CI 3.0-14.1;P<.001)。
- 伐尼克兰组与安慰剂组第9至24周持续戒断率分别为28% vs 7%(aOR 6.0,95%CI 2.1-16.9;P<.001)。
- 伐尼克兰组与增强常规照护组第9至12周持续戒断率分别为51% vs 6%(aOR 16.9,95%CI 6.2-46.3),第9至24周分别为28% vs 4%(aOR 11.0,95%CI 3.1-38.8)。
- 安慰剂组与增强常规照护组的持续戒断率无显著差异。
- 研究药物总体耐受良好;伐尼克兰组2例(2%)和安慰剂组1例(1%)因不良事件停用研究药物;无药物相关严重不良事件;治疗期间出现的不良事件在伐尼克兰组76例(86%)、安慰剂组68例(79%)、增强常规照护组68例(79%)中报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Electronic cigarette use (vaping) among adolescents and young adults is common. Few treatments have been tested in this population. OBJECTIVE: To evaluate the efficacy of varenicline for nicotine vaping cessation in youth who do not smoke tobacco regularly. DESIGN, SETTING, AND PARTICIPANTS: A 3-group randomized clinical trial compared 12 weeks of double-blind varenicline vs placebo, each added to brief, remotely delivered behavioral counseling and compared with single-blind enhanced usual care, with monthly follow-up to 24 weeks. The trial was conducted among youth, aged 16 to 25 years, who vaped nicotine daily or near daily, did not regularly smoke tobacco, and wanted to reduce or quit vaping, in a single US state from June 2022 to May 2024. Data collection ended May 28, 2024. INTERVENTIONS: Participants were randomized (1:1:1) to 12 weeks of varenicline titrated to 1 mg twice daily over 7 days (standard titration), weekly counseling, and referral to text messaging vaping cessation support (This is Quitting [TIQ]) (n = 88); identical placebo, weekly counseling, and referral to TIQ (n = 87); or enhanced usual care (referral to TIQ only) (n = 86). MAIN OUTCOMES AND MEASURES: Biochemically verified continuous vaping abstinence for the last 4 weeks of varenicline treatment vs placebo (primary outcome). Secondary outcomes included bioverified continuous abstinence from weeks 9 through 24 in the varenicline and placebo groups. Additional analyses compared varenicline group and placebo group with enhanced usual care. RESULTS: Of 261 randomized participants (mean age, 21.4 years; 53% female), 254 completed the trial (97.3%). For varenicline and placebo, continuous abstinence rates were 51% vs 14% during weeks 9 through 12 (adjusted odds ratio [aOR], 6.5 [95% CI, 3.0-14.1]; P < .001) and 28% vs 7% during weeks 9 through 24 (aOR, 6.0 [95% CI, 2.1-16.9]; P < .001). Varenicline had higher continuous abstinence rates vs enhanced usual care during weeks 9 through 12 (51% vs 6%; aOR, 16.9 [95% CI, 6.2-46.3]) and during weeks 9 through 24 (28% vs 4%; aOR, 11.0 [95% CI, 3.1-38.8]). Continuous abstinence rates were not significantly different between the placebo and enhanced usual care groups. Study medication was generally well tolerated. Two varenicline participants (2%) and 1 placebo participant (1%) discontinued study medications due to adverse events. No drug-related serious adverse events occurred. Treatment-emergent adverse events were reported by 76 (86%) in the varenicline group, 68 (79%) in the placebo group, and 68 (79%) in the enhanced usual care group. CONCLUSIONS AND RELEVANCE: Varenicline, combined with behavioral counseling, increased vaping abstinence in youth who vape nicotine and do not regularly smoke tobacco. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05367492.
引用
- Evins AE, Cather C, Reeder HT, et al. Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial. JAMA. 2025. PMID: 40266580. doi:10.1001/jama.2025.3810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。